Skip to content

Brickell Biotech rallies; initiated BUY at Lake Street

August 28, 2020

Lake Street Capital initiated Brickell Biotech (BBI +17.2%) with a Buy rating and price target of $6 indicating more than five-folds increase from current levels.

Analyst Thomas Flaten believes that the company has rapidly advanced its lead development program to Phase 3 readiness since becoming public via a reverse merger in 2019.

He further adds that he likes the odds of Brickell’s treatment of primary axillary hyperhidrosis taking on Eli Lilly’s Qbrexza in serving an underappreciated and under-treated disease state affecting a population of ~10M in the U.S.

Investor Presentation of Brickell states that it expects to  initiate pivotal Phase 3 program in Q4; also there is a significant U.S. market opportunity in Hyperhidrosis which affects ~ 4.8% (15.3M) of U.S. population.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: